Search
Cyclophosphamide Treatment Options
A collection of 2183 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
1657 - 1668 of 2183
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Tandem Auto-Allo Transplant for Lymphoma
Completed
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/19/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with monoclonal antibody therapy and radiation therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effecti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2017
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +91 locations
Conditions: Lymphoma
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Completed
CMF (cyclophosphamide, methotrexate, fluorouracil) is used to treat early stage breast cancer. The combination, of these three drugs, has been used for approximately 30 years in the treatment of breast cancer, and has been shown to be safe and effective. It is usually given every 3 weeks. Doctors believe, based on other breast cancer trials, that giving this type of chemotherapy in a shorter amount of time, every 2 weeks or sooner, instead of every 3 weeks, may be better. The purpose of this stu... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/11/2017
Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Breast Cancer
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Completed
The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide. This study will also determine if RG2077 is effective in decreasing disease activity in these patients.
Study hypothesis: CTLA4-Ig mediates a T cell costimulatory blockade that effectively induces an antigen-specific nonresponsiveness in T cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2017
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Completed
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with high-risk hematologic malignancies.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/09/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Leukemia, Multiple Myeloma
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Unknown
This study is a Phase 1 and pharmacologic open-label dose-escalation trial using a "3+3" design. Successive cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified. Once the maximum tolerated dose is identified, an Expansion Cohort will be enrolled at that dose to further characterize safety and pharmacologic endpoints. Additional arms will be enrolled to explore the combination of MM-302 with trastuzumab or trastuzumab plus cyclophospha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: University of California San Francisco, San Francisco, California +4 locations
Conditions: Breast Cancer
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Terminated
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel reduced intensity conditioning regimen. Study population will consist of patients (21 years or under) with hematologic malignancies that have relapsed or are refractory after prior allogeneic transplant. Toxicity will be evaluated by the rate of transplant related mortality an... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
12/28/2016
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hodgkin or Non-Hodgkin Lymphoma, Sarcoma, Myeloid
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Withdrawn
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to non-Hodgkin lymphoma cells. Giving combination chemotherapy together with denileukin diftitox may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with d... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/14/2016
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida
Conditions: Lymphoma
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
Completed
This open-label, 2-arm, nonrandomized, multicenter, Phase Ib study will investigate the safety and efficacy of obinutuzumab (RO5072759; GA101) administered in combination with chemotherapy (bendamustine or fludarabine + cyclophosphamide \[FC\] regimens) in participants with previously untreated cluster of differentiation 20 (CD20)-positive B-CLL. Participants will be enrolled to receive a maximum of 6 cycles of obinutuzumab (1000 milligrams \[mg\] intravenous \[IV\] infusion, on Days 1, 8 and 15... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2016
Locations: Not set, Huntsville, Alabama +17 locations
Conditions: Lymphocytic Leukemia, Chronic
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Alternating treatment with more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine alternating with cyclophosphamide in treating patients who have previously untreated chronic lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +16 locations
Conditions: Leukemia
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Completed
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bor... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
11/30/2016
Locations: Children's Hospital of Alabama, Birmingham, Alabama +170 locations
Conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Completed
This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free survival (PFS) in patients with non-GCB DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2016
Locations: Tower Cancer Research Foundation, Beverly Hills, California +69 locations
Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
1657 - 1668 of 2183